Clinical Trial Update: Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the safety, tolerability, and pharmacokinetic/pharmacodynamic effects of GSK573719 (LAMA) and GW642444 (LABA) when administered alo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK573719
• GW642444 (GW642444)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED